Tadalafil and the recurrence of acute urinary retention

Impact of the association of Tadalafil and Silodosin on the recurrence of acute urinary retention secondary to benign prostate hyperplasia:Randomized double-blind clinical trial

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

PACTR

Registry ID

PACTR202305669258195

Enrollment

Registered

2023-05-05

Start date

2020-06-01

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Urological and Genital Diseases

Interventions

intervention group

control group

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: The study enrolled consenting male patients Aged more than 45 years Presenting acute urinary retention (AUR) (first episode) secondary to benign prostatic hyperplasia (BPH) Not presenting personal history of AUR, prostate cancer, prostatectomy, tumorous duct obstruction, lower urinary tract infection, lower urinary tract surgery, AUR after surgery With no simultaneous use of drugs having interactions with Tadalafil or Silodosine

Exclusion criteria

Exclusion criteria: Patients who did not complete the follow-up Patients in whom a significant prostatic protrusion index was discovered during the study Patients in whom a bladder lithiasis, or bladder diverticulum were discovered

Design outcomes

Primary

Measure	Time frame
To evaluate the safety and efficacy of the combination of Tadalafil and Silodosin compared to Silodosin and placebo in preventing AUR recurrence for patients experiencing an initial episode of acute urinary retention due to benign prostate hyperplasia	—

Secondary

Measure	Time frame
To evaluate the impact on the lower urinary symptom and the sexuality and the quality of life	—

Countries

Tunisia

Contacts

Public ContactAsma Zorgati

Professeur Emergency Department

Zorgatiasma@gmail.com0021650583069

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Aug 9, 2026